Cargando…
Immunotherapy of Neuromyelitis Optica
Neuromyelitis optica (NMO) is a chronic inflammatory disease of the central nervous system that affects the optic nerves and spinal cord resulting in visual impairment and myelopathy. There is a growing body of evidence that immunotherapeutic agents targeting T and B cell functions, as well as activ...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886592/ https://www.ncbi.nlm.nih.gov/pubmed/24455211 http://dx.doi.org/10.1155/2013/741490 |
_version_ | 1782478902254370816 |
---|---|
author | Bienia, Benjamin Balabanov, Roumen |
author_facet | Bienia, Benjamin Balabanov, Roumen |
author_sort | Bienia, Benjamin |
collection | PubMed |
description | Neuromyelitis optica (NMO) is a chronic inflammatory disease of the central nervous system that affects the optic nerves and spinal cord resulting in visual impairment and myelopathy. There is a growing body of evidence that immunotherapeutic agents targeting T and B cell functions, as well as active elimination of proinflammatory molecules from the peripheral blood circulation, can attenuate disease progression. In this review, we discuss the immunotherapeutic options and the treatment strategies in NMO. We also analyze the pathogenic mechanisms of the disease in order to provide recommendations regarding treatments. |
format | Online Article Text |
id | pubmed-3886592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-38865922014-01-22 Immunotherapy of Neuromyelitis Optica Bienia, Benjamin Balabanov, Roumen Autoimmune Dis Review Article Neuromyelitis optica (NMO) is a chronic inflammatory disease of the central nervous system that affects the optic nerves and spinal cord resulting in visual impairment and myelopathy. There is a growing body of evidence that immunotherapeutic agents targeting T and B cell functions, as well as active elimination of proinflammatory molecules from the peripheral blood circulation, can attenuate disease progression. In this review, we discuss the immunotherapeutic options and the treatment strategies in NMO. We also analyze the pathogenic mechanisms of the disease in order to provide recommendations regarding treatments. Hindawi Publishing Corporation 2013 2013-12-25 /pmc/articles/PMC3886592/ /pubmed/24455211 http://dx.doi.org/10.1155/2013/741490 Text en Copyright © 2013 B. Bienia and R. Balabanov. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Bienia, Benjamin Balabanov, Roumen Immunotherapy of Neuromyelitis Optica |
title | Immunotherapy of Neuromyelitis Optica |
title_full | Immunotherapy of Neuromyelitis Optica |
title_fullStr | Immunotherapy of Neuromyelitis Optica |
title_full_unstemmed | Immunotherapy of Neuromyelitis Optica |
title_short | Immunotherapy of Neuromyelitis Optica |
title_sort | immunotherapy of neuromyelitis optica |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886592/ https://www.ncbi.nlm.nih.gov/pubmed/24455211 http://dx.doi.org/10.1155/2013/741490 |
work_keys_str_mv | AT bieniabenjamin immunotherapyofneuromyelitisoptica AT balabanovroumen immunotherapyofneuromyelitisoptica |